Alnylam announces receipt of complete response letter from u.s. fda for supplemental new drug application for patisiran for the treatment of the cardiomyopathy of attr amyloidosis

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the u.s. food and drug administration (fda) has issued a complete response letter (crl) in response to the company's supplemental new drug application (snda) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (attr) amyloidosis. patisiran is the established name for onpattro®, which is approved by the fda for the treatment of t.
ALNY Ratings Summary
ALNY Quant Ranking